ABSTRACT
This chapter describes the theranostic significance of disease-specific CP for the development of novel TSE-EBPT-CPTs in chronic MDR diseases. It also describes unique organ and disease-specific CB inhibitors, CP regulators, CB sequestration inhibitors, and CPS stabilizers as promising CPTs to aid in the prevention and treatment of the ZIKV or other virus-linked diversified spectrum of developmental charnolopathies in newborn infants and Guillain Barre Syndrome in adults. The most recent knowledge of potential PET-RPs in the early theranostics of cancer, CVDs, NDDs, drug addiction, obesity, neurobehavioral disorders, rheumatoid arthritis, and chronic inflammatory illnesses is provided with currently limited theranostic options by highlighting the TSE-EBPT significance of disease-specific CPTs as CP regulators and CBMP modulators. A description of MAO inhibitors, as CP agonists to alleviate PTSD, development of CP targeted PET-RPs, transcriptional regulation of CP/ATG and apoptosis by TFDP3 in BC and hematological diseases for personalized theranostics is provided.
